DR. REDDY'S LABORATORIES LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6,350 INR | +0.98% |
|
+1.55% | +9.52% |
| Sales 2024 * | 279B 3.34B | Sales 2025 * | 299B 3.58B | Capitalization | 1,057B 12.69B |
|---|---|---|---|---|---|
| Net income 2024 * | 54.64B 656M | Net income 2025 * | 56.74B 681M | EV / Sales 2024 * | 3.55 x |
| Net cash position 2024 * | 67.94B 815M | Net cash position 2025 * | 107B 1.28B | EV / Sales 2025 * | 3.18 x |
| P/E ratio 2024 * |
19.3
x | P/E ratio 2025 * |
18.6
x | Employees | 25,863 |
| Yield 2024 * |
0.64% | Yield 2025 * |
0.69% | Free-Float | 91.52% |
More Fundamentals
* Assessed data
More news
Latest transcript on Dr. Reddy's Laboratories Limited
More recommendations
More press releases
More news
| 1 day | +0.98% | ||
| 1 week | +1.55% | ||
| Current month | +2.33% | ||
| 1 month | +3.72% | ||
| 3 months | +5.15% | ||
| 6 months | +20.70% | ||
| Current year | +9.52% |
1 week
6 188.55
6 420.00
1 month
5 881.156 420.00
Current year
5 523.456 505.50
1 year
4 383.406 505.50
3 years
3 655.006 505.50
5 years
2 352.006 505.50
10 years
1 888.006 505.50
| Managers | Title | Age | Since |
|---|---|---|---|
Erez Israeli
CEO | Chief Executive Officer | 57 | 18-04-01 |
Parag Agarwal
DFI | Director of Finance/CFO | - | 20-11-01 |
| Chairman | 56 | 93-01-17 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Gunupati Prasad
CHM | Chairman | 63 | 86-04-07 |
| Chairman | 56 | 93-01-17 | |
Kalpana Morparia
BRD | Director/Board Member | 74 | 07-06-04 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.02% | 6 M€ | +6.07% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-03 | 6,350 | +0.98% | 28,428 |
| 24-05-02 | 6,288 | +1.34% | 8,085 |
| 24-04-30 | 6,205 | -1.40% | 7,153 |
| 24-04-29 | 6,294 | +0.64% | 11,775 |
| 24-04-26 | 6,253 | +0.58% | 8,637 |
Delayed Quote Bombay S.E., May 03, 2024 at 06:00 am EDT
More quotes
Dr. Reddy's Laboratories specializes in developing, producing, and selling pharmaceutical products. Net sales break down by activity as follows:
- sales of generic medications (79.9%): brand-name or generic prescription medications and OTC medicines;
- sales of active ingredients (15.7%). The group also supplies customized pharmaceutical services;
- other (4.4%): sales of generic biopharmaceutical products, development of molecular agents, etc.
Net sales are distributed geographically as follows: India (18.8%), the United States (45%), Russia (9.9%) and other (26.3%).
Sector
Pharmaceuticals
Calendar
2024-05-06
- Q4 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
HOLD
Number of Analysts
35
Last Close Price
6,350
INR
Average target price
6,005
INR
Spread / Average Target
-5.43%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +9.52% | 12.55B | |
| +26.08% | 681B | |
| +21.85% | 556B | |
| -4.77% | 361B | |
| +16.97% | 325B | |
| +5.69% | 285B | |
| +13.68% | 235B | |
| +3.65% | 199B | |
| -11.12% | 189B | |
| -3.40% | 157B |
- Stock Market
- Equities
- DRREDDY Stock
